Company

TriGemX Bio, Inc.

New York-based biotech developing therapies for neurological and metabolic diseases using its Klarity platform, formerly Kallyope.

About

TriGemX Bio, Inc., formerly known as Kallyope Inc., develops therapies for neurological and metabolic diseases using its Klarity platform. Founded in 2015 in New York, US, it received USD 8.2 mn in Grant funding from the Bill & Melinda Gates Foundation Trust on May 11, 2023 and has completed 7 deals, raising USD 236.00 mn in total. In October 2026 it raised USD 94 million in venture funding co-led by TCG Crossover Management, Viking Global Investors and The Column Group, to advance Phase 3 trials of elismetrep for migraine. Stage: Series D.

7Funding rounds

14Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in